Immediate Impact
58 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets
2024 Standout
Works of Jörg Chromik being referenced
Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy
2021
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jörg Chromik | 273 | 45 | 108 | 145 | 16 | 346 | |
| Rosa Marı́a Arana-Trejo | 340 | 62 | 85 | 191 | 12 | 397 | |
| Margarete A. Fabre | 220 | 28 | 106 | 162 | 17 | 371 | |
| Catherine Garnett | 224 | 65 | 82 | 84 | 12 | 350 | |
| J. Janssen | 268 | 30 | 73 | 209 | 11 | 389 | |
| PH Fitzgerald | 277 | 62 | 105 | 237 | 14 | 390 | |
| Peter Nöllke | 295 | 57 | 190 | 108 | 13 | 360 | |
| Feng Wang | 311 | 33 | 119 | 154 | 11 | 373 | |
| Vicky Sandhu | 266 | 26 | 127 | 78 | 15 | 348 | |
| J. Maciejewski | 257 | 33 | 176 | 105 | 10 | 338 | |
| Ulrich Pascheberg | 205 | 32 | 138 | 76 | 12 | 320 |
All Works
Loading papers...